Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance.

Parayath, Neha N; Gandham, Srujan K; Amiji, Mansoor M

Parayath, Neha N; Gandham, Srujan K; Amiji, Mansoor M.

Afiliación

Parayath NN; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Gandham SK; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
Amiji MM; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.

Nanomedicine (Lond) ; 17(19): 1355-1373, 2022 08.

Article en En | MEDLINE | ID: mdl-36255330

miRNAs are the messenger molecules with the tumor that have significant influence on the cancer growth and progression. Many strategies have been evaluated to modulate these messengers artificially to obstruct cancer growth and destroy cancer cells. This review discusses one such strategy to deliver these messenger miRNAs using hyaluronic acid-based nanoparticles that harness the body's own immune system to fight cancer. The two miRNAs that this review discusses are miRNA-125b and miRNA-let7b.

Asunto(s)

MicroARNs; Neoplasias; Humanos; MicroARNs/genética; MicroARNs/uso terapéutico; Nanomedicina; Resistencia a Antineoplásicos; Ácido Hialurónico; Neoplasias/tratamiento farmacológico; Neoplasias/genética; Microambiente Tumoral

Palabras clave

hyaluronic acid nanoparticles; miRNA-125b; miRNA-let7b; miRNAs; polyethyleneimine; tumor-associated macrophages

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: MicroARNs / Neoplasias Límite: Humans Idioma: En Revista: Nanomedicine (Lond) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google